Skip to main content

Table 4 Correlation between PIK3CA mutation and clinical variables in estrogen receptor (ER)-positive and ER-negative tumors

From: PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer

  

Patients with ER-negative breast cancer

Patients with ER-positive breast cancer

  

PIK3CA wild-type (n = 54)

PIK3CA mutation (n = 8)

P valuea

PIK3CA wild-type (n = 63)

PIK3CA mutation (n = 15)

P valuea

Pathological complete response (pCR) versus residual disease (RD)

RD

38 (72%)

5 (71%)

1.000

57 (92%)

13 (87%)

0.617

 

pCR

15 (28%)

2 (29%)

 

5 (8%)

2 (13%)

 
 

Unknown

1

1

-

1

-

-

Residual cancer burden

0

15 (34.1%)

2 (50.0%)

0.616 (0.527b)

5 (10.6%)

2 (18.2%)

0.221 (0.543b)

 

I

3 (6.8%)

0 (0%)

 

4 (8.5%)

0 (0%)

 
 

II

15 (34.1%)

2 (50.0%)

 

22 (46.8%)

8 (72.7%)

 
 

III

11 (25.0%)

0 (0%)

 

16 (34.0%)

1 (9.1%)

 
 

Unknown

10

4

-

16

4

-

HER2 status

HER2-

47 (87%)

7 (88%)

1.000

57 (90%)

14 (93%)

0.617

 

HER2+

7 (13%)

1 (12%)

 

6 (10%)

1 (7%)

 

Grade

Grade 1–2

9 (20%)

2 (33%)

0.598

37 (71%)

8 (67%)

0.739

 

Grade 3

36 (80%)

4 (67%)

 

15 (29%)

4 (33%)

 
 

Unknown

9

2

-

11

3

-

Nodal status

Negative

15 (28%)

4 (50%)

0.235

14 (22%)

8 (53%)

0.025

 

Positive

39 (72%)

4 (50%)

 

49 (78%)

7 (47%)

 

Tumor size

T0

0 (0%)

0 (0%)

0.937

1 (2%)

1 (7%)

0.715

 

T1

4 (7%)

0 (0%)

 

3 (5%)

0 (0%)

 
 

T2

26 (48%)

4 (50%)

 

33 (52%)

8 (53%)

 
 

T3

10 (18%)

1 (12%)

 

8 (13%)

2 (13%)

 
 

T4

14 (26%)

3 (38%)

 

18 (28%)

4 (27%)

 

Ethnicity

Asian

1 (2%)

0 (0%)

0.326

1 (2%)

1 (7%)

0.478

 

Black

6 (11%)

2 (25%)

 

5 (8%)

0 (0%)

 
 

Hispanic

16 (30%)

4 (50%)

 

24 (38%)

6 (40%)

 
 

Caucasian

31 (57%)

2 (25%)

 

33 (52%)

8 (53%)

 

Median age (minimum-maximum), years

 

51 (28–73)

56.5 (42–73)

-

50 (28–73)

52 (43–73)

 
  1. aChi-square test. b P value for comparison of residual cancer burden (RCB)-0 and RCB-I versus RCB-III. PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide.